Faculty Bibliography
Searched for:
in-biosketch:true
person:losick01
Total Results:
226
Journal of the American Academy of Dermatology. 2021:84(6):1769-1772.DOI: 10.1016/j.jaad.2020.10.098
Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis
PMCID:7797175
PMID: 33440213
ISSN: 1097-6787
CID: 4835312
CCL20 in Psoriasis: A Potential Biomarker of Disease Severity, Inflammation, and Impaired Vascular Health
BACKGROUND:Psoriasis is associated with increased cardiovascular risk that is not captured by traditional pro-inflammatory biomarkers. OBJECTIVE:To investigate the relationship between psoriasis area and severity index (PASI), circulating pro-inflammatory biomarkers, and vascular health in psoriasis. METHODS:In psoriasis and age, sex-matched controls, 273 proteins were analyzed utilizing the OLINK platform, while vascular endothelial inflammation and health was measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS:= 48.18, p<0.001) in predicting vascular endothelial inflammation. LIMITATIONS/CONCLUSIONS:Our study was observational and does not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION/CONCLUSIONS:We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
PMID: 33259876
ISSN: 1097-6787
CID: 4694102
A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal [Case Report]
PMCID:7806540
PMID: 33490340
ISSN: 2352-5126
CID: 4771702
Laboratory Testing in Telogen Effluvium
Telogen effluvium (TE) – a common cause of non- scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices.
PMID: 33400415
ISSN: 1545-9616
CID: 4738752
Response to "Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma (PRP)" [Letter]
PMID: 32858078
ISSN: 1097-6787
CID: 4576022
Response to "Variables affecting the potential efficacy of platelet-rich plasma in dermatology" [Letter]
PMID: 32858079
ISSN: 1097-6787
CID: 4734372
Paradoxical Mucositis Associated With Anti-Tumor Necrosis Factor Therapy
PMID: 31524852
ISSN: 1536-7355
CID: 4088952
Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report [Case Report]
PMCID:7543927
PMID: 33052310
ISSN: 2352-5126
CID: 4735072
Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients
PMCID:7489404
PMID: 32876656
ISSN: 2168-6084
CID: 4614582
Journal of the American Academy of Dermatology. 2020:83(5):1298-1303.DOI: 10.1016/j.jaad.2020.07.006
Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial
BACKGROUND:Platelet-rich plasma (PRP) shows promise as an androgenetic alopecia (AGA) treatment. OBJECTIVE:Conduct a randomized placebo-controlled split-scalp study to investigate PRP's effects on hair regrowth and thickness. METHODS:35 study participants with AGA had two 7.6-centimeter x 7.6-centimeter squares tattooed on their scalps. Areas were randomly assigned to intradermal injection with PRP or saline. Subjects underwent three monthly treatment sessions with evaluation three months after final treatment. RESULTS:(p < 0.05). There was no significant difference in hair density change between the two groups (p > 0.05). No serious adverse events were reported. LIMITATIONS/CONCLUSIONS:Possible PRP diffusion due to split-scalp study design as well as microinjections causing micro-injury to both sides. CONCLUSION/CONCLUSIONS:PRP may have benefit in increasing hair density.
PMID: 32653577
ISSN: 1097-6787
CID: 4527682
